Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
:CSTL
CSTL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.97 - $35.84
Previous CloseN/A
Volume108.23K
Average Volume (3M)377.33K
Market Cap
$595.07M
Enterprise Value$538.14M
Total Cash (Recent Filing)-$1.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)33.7
Beta0.59
Next Earnings
May 05, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.61
Shares Outstanding28,844,936
10 Day Avg. Volume419,303
30 Day Avg. Volume377,326
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.76
Price to Cash Flow (P/CF)6.00
P/FCF Ratio6.00
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.62
Enterprise Value/Ebitda14.11
Forecast
1Y Price Target
$39.00Price Target Upside89.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Castle Biosciences News
PremiumCompany Announcements
Castle Biosciences’ 2024 Earnings: Growth Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Market PotentialCSTL shares trade at a significantly lower valuation compared to its clinical peers, suggesting potential undervaluation.
Revenue GrowthCastle Biosciences reported 4Q24 results that were ahead of expectations and consensus, with total revenue of $86.3 million driven by increased year-over-year volumes for most of its tests.
Bears Say
Coverage DecisionNovitas' negative DDx-SCC coverage decision means minimal reimbursement going forward.
Reimbursement UncertaintyThere is uncertainty regarding the SCC reimbursement status, which could impact CSTL's profitability.
Volume Growth ConcernsSoftness in 4Q DDx-CM volume growth has investors concerned about the growth outlook.
---
Ownership Overview
2.72% Insiders
27.49% Mutual Funds
0.25% Other Institutional Investors
55.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $16.96 and its highest was $35.84 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $595.07M.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is May 05, 2025 which is in 7 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on Feb 27, 2025. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.047 by $0.273.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -0.07.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 28,844,936 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of $0.32 in its last earnings report, beating expectations of $0.047. Following the earnings report the stock price went down -14.241%.
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
---
Castle Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.00 (89.05% Upside)
$39.00 (89.05% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 92.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.74%
12-Months-Change
Fundamentals
Return on Equity
4.31%
Trailing 12-Months
Asset Growth
15.93%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
---
CSTL Company Deck
---
CSTL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Castle Biosciences reported strong revenue growth and profitability in 2024, with significant increases in test report volumes and cash reserves. However, the anticipated loss of Medicare coverage for DecisionDx-SCC poses a challenge, along with expected declines in the mental health segment. Despite these challenges, the company shows strong financial health and growth potential.Read More>---
CSTL Stock 12 Month Forecast
Average Price Target
$39.00
▲(89.05% Upside)
Technical Analysis
Best Analysts Covering CSTL
1 Year
1 Year Success Rate
10/19 ratings generated profit
1 Year Average Return
+14.73%
reiterated a buy rating 2 months ago
Copying Sung Ji Nam's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +14.73% per trade.
---